^
    Back
    Association details:
    Biomarker:EGFR amplification
    Cancer:Esophageal Cancer
    Drug Class:EGFR inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ESMO 2021
    Title:

    1421P - EGFR inhibition in EGFR-amplified esophagogastric cancer (EGC): Retrospective global experience

    Published date:
    09/13/2021
    Excerpt:
    Pts with EGFR-amplified EGC derive clinical benefit from EGFR inhibition, which is most pronounced in the absence of intrinsic resistance mechanisms.